Sinopharm Hyundai announced that it is expected to achieve net profit attributable to shareholders of listed companies of 245 million yuan to 305 million yuan from January to June 2026, a year-on-year decrease of 63.54% to 54.61%. Currently, the field of antibiotic intermediates and APIs is experiencing multiple challenges. On the one hand, it is influenced by international geopolitics, leading to protectionism in overseas markets; on the other hand, excessive domestic antibiotic production capacity and collection effects are transmitted upstream of the industrial chain, and the operating pressure on the industry has increased significantly.

Sinopharm Hyundai announced that it is expected to achieve net profit attributable to shareholders of listed companies of 245 million yuan to 305 million yuan from January to June 2026, a year-on-year decrease of 63.54% to 54.61%. Currently, the field of antibiotic intermediates and APIs is experiencing multiple challenges. On the one hand, it is influenced by international geopolitics, leading to protectionism in overseas markets; on the other hand, excessive domestic antibiotic production capacity and collection effects are transmitted upstream of the industrial chain, and the operating pressure on the industry has increased significantly.